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Randomized study
Pharmacokinetic
safety
InfantsMethods: Subjects (N ¼ 37) were randomized to either rufinamide or any other approved
AED chosen by the investigator as adjunctive therapy to the subject's existing regimen
of 1e3 AEDs.
Results: Interim safety results showed that treatment-emergent adverse events (TEAEs)
were similar between the rufinamide (22 [88.0%]) and any-other-AED group (9 [81.8%]), with
most events considered mild or moderate. A population PK analysis was conducted
including plasma rufinamide concentrations from Study 303 and two other study pop-
ulations of LGS subjects 4 years. The rufinamide PK profile was dose independent. The
apparent clearance (CL/F) estimated from the PK model was 2.19 L/h; it was found to in-
crease significantly as a function of body weight. Coadministration of valproic acid
significantly decreased rufinamide CL/F. CL/F was not significantly affected by other
concomitant AEDs, age, gender, race, hepatic function, or renal function. No adjustments
to body weight-based rufinamide dosing in subjects 1 to <4 years are necessary.
Significance: Rufinamide was safe and well tolerated in these pediatric subjects. Results
from the interim analysis demonstrate that rufinamide's safety and PK profile is compa-
rable in subjects 1 to <4 and 4 years with LGS.
Clinical Trial Registration: Study 303 (clinicaltrials.gov: NCT01405053).
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology
Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rufinamide, a triazole derivative that is structurally different
from currently available antiepileptic drugs (AEDs), is indi-
cated for adjunctive treatment of seizures associated with
Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of
age and older, and in adults.1 Findings from a double-blind,
placebo-controlled study in subjects 4 years of age with
inadequately controlled LGS provided the primary basis for
rufinamide approval as adjunctive therapy in LGS.2 This
12-week study demonstrated the safety and tolerability of
rufinamide as well as its efficacy compared to placebo in all
primary efficacy variables d percentage change in total
seizure frequency, toniceatonic seizure frequency, and
seizure severity rating d in subjects with a median age of 12
years.2 Pharmacokinetic (PK) data from this study also
demonstrated that higher plasma concentrations of rufina-
mide were associated with decreased seizure frequency and
severity. Rufinamide clearance was decreased when it was
coadministered with valproic acid; clinically relevant changes
in rufinamide PK parameters were not observed when it was
coadministered with other AEDs.1
LGS is a rare but potentially catastrophic childhood
epileptic encephalopathy.3,4 The onset of LGS usually occurs
before the age of 8 years. An initial diagnosis of LGS consti-
tutes <1% of childhood epilepsies; as disease presentation
evolves into an LGS pattern over time, the prevalence in-
creases to 4%.4e7 LGS typically includes a triad of features:
multiple seizure types (including tonic seizures), specific
electroencephalogram (EEG) pattern (slow spike-and-wave
complex), and cognitive impairment or intellectual
disability/delayed development.5,6,8 LGS also includes “drop
attacks,”which can be caused by seizure types such as tonic or
atonic, and may dramatically increase the risk for serious
injury due to sudden falls.4,5,9 In the absence of a biologicalmarker and given the multiple etiologies that can be at the
origin of the syndrome, a firm diagnosis of LGS may prove to
be very difficult in very young children. However, a number of
symptoms and signs suggesting progression of the epilepsy
phenotype may alert experienced clinicians and help appro-
priately determine treatment choices.5 Furthermore, although
the most characteristic type of seizure in LGS is the tonic
type,5 tonic seizures are not necessarily evident at onset, with
reports of their occurrence varying widely, from 17% to 95%.10
Other seizure types, including atypical absence, atonic, ton-
iceclonic, andmyoclonic, may also occur in patientswith LGS.
Cognitive and psychosocial dysfunctions are also clinically
salient features of LGS in children, with as many as 20e60% of
sufferers experiencing mental impairment at the time of LGS
onset and up to 75e96% having such impairments by 4e5
years after onset.5,9,11
There is a lack of studies on treatment efficacy and
tolerability among infants and young children with severe
epileptic encephalopathies; therefore, elucidating the safety,
tolerability, and age group-specific pharmacokinetics of
rufinamide in pediatric patients 1 to <4 years of age is
important. LGS is an epilepsy syndrome that develops pro-
gressively. New types of seizures enrich the clinical symp-
toms observed at onset, and cognitive deficits progressively
become evident.5 Evidence that an AED known to be effica-
cious in LGS can be used safely in younger children with
drug-resistant LGS may prove to have a substantial impact
on the overall evolution of the syndrome. A Phase III, ran-
domized, active-controlled study evaluating the safety,
pharmacokinetics, and cognitive and behavioral effects of
rufinamide (vs any other AED adjunctive therapy chosen by
the investigator) in pediatric subjects aged 1 to <4 years
with inadequately controlled LGS (Study 303) is currently
underway. This manuscript reports 6-month interim safety
and PK results of that study.
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2.1. Aims
Study 303 (clinicaltrials.gov: NCT01405053) is an ongoing
Phase III, multicenter, randomized, active-controlled, open-
label, 2-year study designed to evaluate the safety, pharma-
cokinetics, and cognitive/behavioral effects of adjunctive
rufinamide treatment for control of seizures associated with
inadequately controlled LGS in a pediatric population (1 to
<4 years of age). It is from this study that the reported 6-
month interim safety and PK analysis was generated.2.2. Study population
The study enrolled patients across 20 centers in North
America and the European Union (Supplementary Table 1). All
participants met the following criteria:
 1 to <4 years of age;
 Clinical diagnosis (according to investigator) of LGS, which
might include the presence of multiple types of seizures
progressively enriching the clinical picture, a slow back-
ground EEG rhythm, slow spike-wave pattern (<3 Hz), and/
or the presence of polyspikes. In very young patients, in-
vestigators were requested to use their best educated
judgment on the possible evolution of potential candidates
into full-blown LGS before enrolling a subject.
 Patients diagnosed with benign myoclonic epilepsy of in-
fancy, atypical benign partial epilepsy (pseudo-Lennox
syndrome), or continuous spike-waves of slow sleep, as
well as other epilepsy syndromes not suggesting the elec-
troclinical profile of patients within the LGS spectrum,
were excluded; and
 A fixed dose of 1e3 concomitant AEDs for a minimum of 4
weeks before randomization, with inadequate response to
treatment and documentation of consistent seizures.
Additionally, subjectswith familial short QT syndrome and
those with prior treatment with rufinamide were excluded.
Study 303 adheres to the principles of the Declaration of
Helsinki, European Agency for the Evaluation of Medicinal
Products, United States Code of Federal Regulations, and Eu-
ropeanGood Clinical Practice and Clinical Trial Directives, and
was approved by the institutional review boards at all sites.
Written informed consent was obtained from the guardian/
legally authorized representative of each subject.2.3. Study design
After screening, eligible subjects were randomized and then
entered treatment for 106 weeks; an 8-week pre-
randomization phase included a screening period and base-
line visit, and a 106-week randomization phase included
titration and maintenance (Fig. 1). Subjects who completed
the screening period and displayed inadequately controlled
toniceatonic seizures characteristic of LGS at the baseline
visit were randomized in a 2:1 ratio to either rufinamide or anapproved AED chosen by the investigator as adjunctive ther-
apy to the subject's existing regimen of 1e3 AEDs.
Study treatment included: (1) rufinamide up to 45 mg/kg/
day, in two divided doses, administered as oral suspension
(40 mg/mL) added to existing regimen of 1e3 AEDs; or (2)
adjunctive AED: any approved, investigator-chosen AED
dosed according to the investigator's usual practice and added
to a subject's existing regimen of 1e3 AEDs. Dose titration,
maintenance, and tapering were handled in accordance with
the current Prescribing Information for rufinamide.1 Rufina-
mide was administered at 10 mg/kg/day (BID) and increased
by 10 mg/kg every 3 days to 40 mg/kg/day, then increased by
5 mg/kg to the target maintenance level of 45 mg/kg/day
(Supplementary Table 2). If tolerability issues arose, titration
could occur more slowly, and the target dose was reduced
based on investigators' discretion. The dose of rufinamide
used in this study has been shown to be effective and well
tolerated in tablet form in subjects at least 4 years of age, and
has been approved for use in the United States1 and in other
countries.12 In addition, the oral suspension has demon-
strated bioequivalence with the tablet formulation.13
Study 303 has three primary objectives: (1) to evaluate the
overall safety and tolerability of rufinamide in pediatric sub-
jects1 to <4 years of agewith inadequately controlled LGS by
comparing the effect of two drug regimens d rufinamide or
any other approved AED chosen by the investigator as add-on
therapy to the subject's existing regimen of 1e3 AEDs; (2) to
characterize the age group-specific pharmacokinetics of rufi-
namide using a population approach; and (3) to examine the
cognitive and behavioral effects of rufinamide in this pediatric
population.2.4. Safety assessments
Safety assessments were performed on a regular basis and
included monitoring and recording of all adverse events,
including treatment-emergent and serious adverse events
(TEAEs; SAEs) using Medical Dictionary for Regulatory Activ-
ities (MedDRA) standardized terms and regular monitoring of
hematology, blood chemistry, and urine values. In addition,
periodic assessments of vital signs and 12-lead electrocar-
diograms (ECGs) were performed.2.5. Pharmacokinetics
Blood sampling was performed for the assessment of rufina-
mide plasma concentrations during the maintenance period.
A population PK analysis using non-linear mixed effect
modeling in NONMEM v7.2, was conducted and included
plasma rufinamide concentrations from several study
populations:
 Subjects with LGS aged 1 to <4 years from Study 303
(described above)
 Subjects with LGS aged 4 years from Study 022 (multi-
center, double-blind, placebo-controlled study of rufina-
mide as adjunctive therapy in subjects aged 4 years with
inadequately controlled seizures associated with LGS in
nine countries)2
Fig. 1 e Study design. AED ¼ antiepileptic drug.
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blind, placebo-controlled, comparative study of rufinamide
in Japanese subjects aged 4 years with LGS)14
Due to the sparse nature of the PK sampling scheme, it was
not possible to characterize the absorption phase of the PK
profile. Therefore, a constant input model (constant-infusion)
parameterized in terms of clearance (CL/F) was the starting
point for the PK structural base model. The interindividual
variability (IIV) (h, ETA) was assessed using an exponential
error structure, assuming normal distribution of this param-
eter. Interoccasion variability by study visit was also tested on
clearance. The residual variability ( 3) was assessed by additive,
proportional, and combined additive/proportional error
structures. All permutations of interindividual and residual
variability error structures were tested systematically. The
estimation method used was first-order conditional estima-
tion with interaction.
The effects of the following covariates were investigated:
demographics (gender, race, age [both as continuous and
categorical], and body weight), renal function (creatinine
clearance; CRCL), and liver function (alkaline phosphatase,
and bilirubin). Concomitant administrations of other AEDs
such as carbamazepine, lamotrigine, phenytoin, and valproic
acid were evaluated as categorical covariates. Plasma con-
centrations of valproic acid were also evaluated as a contin-
uous covariate. For subjects older than 16 years of age, CRCL
was calculated using the CockcrofteGault formula.15 For
subjects between 1 and 16 years of age, CRCL was calculatedusing the formula suggested by TraubeJohnson.16 The asso-
ciation between subject covariates and PK parameters was
evaluated in a stepwise fashion: 1) individual Bayes post hoc
PK parameter estimates were generated from the base model.
The difference of individual estimates from the corresponding
population value (h) was plotted versus the covariates to
identify potential relationships; 2) h-shrinkage was calculated
and reported for IIV parameters estimated by the model. A
parameter with shrinkage >30% was excluded from the co-
variate analysis; 3) covariates identified as being important
were first assessed in the basic model by univariate addition
and ranked in descending order according to the change in
objective function value. All significant variables were then
tested in a full model, and a subsequent backwards deletion
was carried out at the 0.1% significance level, where the
relative influence of each covariate on the model was reeval-
uated by deleting it from the full model on an individual basis.
The final population PK model was evaluated for perfor-
mance using graphical assessment, nonparametric boot-
strapping, and visual predictive checks. The resulting
parameters from the final PK model were used for calculation
of individual derived values of rufinamide steady-state expo-
sure (Cav) as follows:
Cav ¼ ½DOSE=Dosing interval=CL=F
where DOSE is the amount of rufinamide in mg during the main-
tenance phase and CL/F in L/h is the model-predicted individual
apparent clearance. The calculated Cav values were used in the
graphical exploration of PK/PD relationships for efficacy and safety.
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compiled after the database cutoff date of February 28, 2014,
and report results of the 6-month safety and population PK
analysis of rufinamide in this pediatric population. Analysis of
cognitive endpoints will be reported at the end of the 2-year
study.3. Results
3.1. Demographics
A total of 37 subjects were randomized to treatment: 25 to the
rufinamide group and 12 to the any-other-AED group. All
subjects randomized to rufinamide and all but one random-
ized to any other AED received at least one dose of study drug
(this one subject was not included in the final analysis). Sub-
ject demographics and other baseline characteristics are
shown in Table 1. The pediatric population consists of 36
subjects (rufinamide¼ 25; any-other-AED group¼ 11). Overall,
most subjects were 1 to <3 years old (12e35 months), male,
and white, which was consistent in both treatment groups at
baseline and reflected the racial and ethnic distribution of the
patient population in the countries/sites participating in theTable 1 e Demographics and baseline characteristics.
Category Rufinamide
(N ¼ 25)
Any-other-AED
(N ¼ 11)
Total
(N ¼ 36)
Agea (months)
Mean (SD) 28.3 (10.0) 31.3 (8.7) 29.2 (9.6)
Median 28.0 31.0 30.5
Min, max 12, 46 16, 47 12, 47
Age group, n (%)
12e35 months 17 (68.0) 7 (63.6) 24 (66.7)
36e48 months 8 (32.0) 4 (36.4) 12 (33.3)
Sex, n (%)
Male 14 (56.0) 9 (81.8) 23 (63.9)
Female 11 (44.0) 2 (18.2) 13 (36.1)
Race, n (%)
White 23 (92.0) 8 (72.7) 31 (86.1)
Black or African
American
2 (8.0) 2 (18.2) 4 (11.1)
Seizure type,b n (%)
Partial 15 (60.0) 6 (54.5) 21 (58.3)
Absencec 5 (20.0) 4 (36.4) 9 (25.0)
Atypical absence 12 (48.0) 6 (54.5) 18 (50.0)
Myoclonic 15 (60.0) 9 (81.8) 24 (66.7)
Clonic 6 (24.0) 4 (36.4) 10 (27.8)
Toniceatonic 15 (60.0) 7 (63.6) 22 (61.1)
Primary
generalized
toniceclonic
6 (24.0) 3 (27.3) 9 (25.0)
Other 9 (36.0) 1 (9.1) 10 (27.8)
Percentages are based on the total number of subjects with non-
missing values in relevant treatment group.
AED ¼ antiepileptic drug; max ¼ maximum; min ¼ minimum;
SD ¼ standard deviation.
a Age was calculated at date of informed consent.
b Subjects could have had more than one type of seizure.
c Although not specifically categorized as such, all “absence sei-
zures” were atypical.study. Mean weight at baseline was 12.9 kg, and mean time
since diagnosis was 21.4 months. Baseline seizure types were
generally similar between groups. The studywas conducted at
20 sites: United States (8), Canada (1), France (2), Greece (2),
Italy (4), and Poland (3).
3.2. Concomitant medications
Overall at baseline, 8.3% of subjects took 1 AED, 36.1% took 2
AEDs, 47.2% took 3 AEDs, 2.8% took 4 AEDs, and 5.6% took 5
AEDs. The concomitant AEDs taken most commonly (>25% of
subjects in either treatment group) were valproic acid, leve-
tiracetam, topiramate, diazepam, vigabatrin, and clobazam
(Table 2).
The add-on AEDs chosen by the investigator at the time of
randomization for the 11 subjects in the any-other-AED group
were lamotrigine in 5 (45.5%) subjects; clobazam in 2 (18.2%)
subjects; and phenobarbital, topiramate, valproic acid, and
zonisamide in 1 (9.1%) subject each. To compare the profile of
AEDs other than rufinamide administered to subjects in both
treatment groups, the add-on AEDs chosen by the investigator
at the time of randomization were added to the baseline AEDs
for subjects in the any-other-AED group. As a result of this
process, the two treatment groups displayed similar treat-
ment profiles with respect to AEDs other than rufinamide,
permitting a meaningful assessment of the effects of
adjunctive rufinamide.
3.3. Safety
Total TEAE incidence was similar between the rufinamide
group (88.0%) and the any-other-AED group (81.8%) (Table 3).
The majority of subjects in both treatment groups had TEAEs
that were considered mild (36.0% in the rufinamide group and
36.4% in the any-other-AED group) or moderate (44.0% in the
rufinamide group and 27.3% in the any-other-AED group). The
most frequently reported TEAEs (occurring in 10% of sub-
jects) are shown in Table 3. In the rufinamide treatment group
these events were vomiting (24.0%), upper respiratory tract
infection (20.0%), diarrhea and somnolence (16.0% each), and
constipation, cough, bronchitis, rash, and decreased appetite
(12.0% each). In the any-other-AED group, they were diarrhea
and upper respiratory tract infection (27.3% each), and
convulsion (18.2%). Eight (32.0%) subjects in the rufinamide
group and 3 (27.3%) subjects in the any-other-AED group had
TEAEs requiring study drug dose adjustment or interruption.
SAEs occurred in 6 (24.0%) and 3 (27.3%) subjects in the
rufinamide and any-other-AED groups, respectively. Bron-
chopneumonia (1 subject in each group) and convulsions (2
subjects in the any-other-AED group) were the only SAEs re-
ported in more than 1 subject. All subjects recovered from
their SAEs without sequelae. TEAEs that resulted in discon-
tinuation occurred in 2 of 25 subjects (8.0%) in the rufinamide
group (vomiting and decreased appetite) and 1 of 11 subjects
(9.1%) in the any-other-AED group (rash). Reported TEAEs of
special interest in the rufinamide group were weight loss (2
subjects), skin reactions (5 subjects), somnolence (4 subjects),
and fatigue (1 subject). No TEAEs of cardiac and electrocar-
diographic events, pancreatitis, liver toxicity, growth and
development, coordination, or leukopenia occurred in the
Table 2 e Baseline use of antiepileptic drugs.
Drug name Rufinamide (N ¼ 25) Any-other-AED (N ¼ 11)
Baseline n (%) Baseline n (%) Randomizationa n (%) Total n (%)
Valproic acid 17 (68.0) 5 (45.5) 1 (9.1) 6 (55)
Levetiracetam 6 (24.0) 8 (72.7) 0 8 (73)
Topiramate 9 (36.0) 2 (18.2) 1 (9.1) 3 (27)
Diazepam 4 (16.0) 3 (27.3) 0 3 (27)
Vigabatrin 7 (28.0) 0 0 0
Clobazam 3 (12.0) 3 (27.3) 2 (18.2) 5 (45)
Lamotrigine 5 (20.0) 1 (9.1) 5 (45.5) 6 (55)
Clonazepam 3 (12.0) 1 (9.1) 0 1 (9)
Nitrazepam 2 (8.0) 1 (9.1) 0 1 (9)
Oxcarbazepine 2 (8.0) 1 (9.1) 0 1 (9)
Ethosuximide 2 (8.0) 0 0 0
Phenobarbital 1 (4.0) 1 (9.1) 1 (9.1) 2 (18)
Zonisamide 1 (4.0) 1 (9.1) 1 (9.1) 2 (18)
Valproic acid (Ergenyl chrono) 0 1 (9.1) 0 1 (9)
Lacosamide 0 1 (9.1) 0 1 (9)
Lorazepam 0 1 (9.1) 0 1 (9)
Midazolam 1 (4.0) 0 0 0
Primidone 1 (4.0) 0 0 0
Subjects with 2 or more medications within a class level and drug name were counted only once within that class level and drug name. AEDs at
baseline were defined as AEDs starting prior to first dose date and ending on or after first dose date.
AED ¼ antiepileptic drug.
a Add-on AEDs chosen by the investigator at the time of randomization for subjects in the any-other-AED group.
Table 3 e Overview of adverse events from study 303.
Category Rufinamide
(N ¼ 25) n (%)
Any-other-AED
(N ¼ 11) n (%)
Subjects with:
Any TEAE 22 (88.0) 9 (81.8)
Severe TEAEs 2 (8.0) 2 (18.2)
SAEs 6 (24.0) 3 (27.3)
TEAEs occurring in at least 10% of subjects, by preferred term
Vomiting 6 (24.0) 1 (9.1)
Upper respiratory
tract infection
5 (20.0) 3 (27.3)
Diarrhea 4 (16.0) 3 (27.3)
Somnolence 4 (16.0) 0 (0.0)
Constipation 3 (12.0) 1 (9.1)
Cough 3 (12.0) 1 (9.1)
Bronchitis 3 (12.0) 0 (0.0)
Rash 3 (12.0) 1 (9.1)
Decreased appetite 3 (12.0) 1 (9.1)
Convulsion 1 (4.0) 2 (18.2)
TEAEs are ordered by decreasing frequency with which they
occurred in the rufinamide group.
AED ¼ antiepileptic drug; SAE ¼ serious adverse event;
TEAE ¼ treatment-emergent adverse event.
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any-other-AED group were skin reactions and fatigue (1 sub-
ject each). No subjects died or had AEs that resulted in death
as of the data cutoff date in either treatment group. Addi-
tionally, there were no clinically important mean changes in
laboratory values, vital signs, or ECGs.
3.4. Population PK analysis: studies 303, 022, and 304
The PK population consisted of 115 subjects with LGS: subjects
aged 1 to <4 (n ¼ 24, Study 303) and 4 years (n ¼ 65, Study
022; n ¼ 26, Study 304). Overall subject characteristics are
shown in Supplementary Table 3. The mean age was 12.6
(range 1e35) years, and the mean rufinamide dose was
1315mg/day (range 160e4400). Among the total population, 47
(40.9%) were female and 75 (65.2%) were white. Coadminis-
tered AEDs (subjects could be on 1e3 concomitant AEDs) in
the PK population included: carbamazepine (CYP3A4 inducer),
15 subjects (13.0%); lamotrigine, 37 subjects (32.2%); valproic
acid, 76 subjects (66.1%); phenytoin (CYP3A4 inducer), 16
subjects (13.9%).
Because of a lack of samples during the absorption phase of
the PK profile, it was not possible to characterize the absorp-
tion of rufinamide in the study population. Therefore, a
constant-input model parameterized in terms of apparent
clearance (CL/F) was used, which adequately characterized
the PK profile of rufinamide. The PK profile of rufinamide was
dose independent, and the estimated basal CL/F from the PK
model was 2.19 L/h; 95% confidence interval (CI): 1.94e2.44
(Supplementary Table 4). CL/F was found to increase signifi-
cantly as a function of body weight: estimated exponent
weight effect on CL/F ¼ 0.831; 95% CI: 0.704e0.958. Coadmin-
istration of valproic acid significantly decreased the CL/F of
rufinamide with a slope of 0.496 (95% CI: e0.704 to 0.288);this effect confirms what has already been observed in sub-
jects 4 years of age and investigated in vitro.1,17,18 Interin-
dividual variability in CL/F was mild to moderate (33.3%). The
additive residual error had an estimated standard deviation
(SD) of 4.31 mg/mL. CL/F was not significantly affected by other
concomitant AEDs or by age, gender, race, hepatic function, or
renal function. Rufinamide clearance and exposure in subjects
aged1 to <4 years were comparable to those in subjects aged
4 years (Fig. 2). In subjects receiving concomitant valproic
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 3 9 3e4 0 2 399acid, median model-derived rufinamide steady-state expo-
sure (Cav) and area under the concentrationetime curve (AUC)
values were also comparable across different age groups
(Fig. 3 and Supplementary Table 4). However, model-derived
exposure estimates (Cav and AUC values) were 13.9e33.0%
higher in subjects receiving valproic acid across all age groups
(Supplementary Table 5).4. Discussion
The purpose of this ongoing study is to characterize the ef-
fects of rufinamide in the pediatric population 1 to <4 years
of age with inadequately controlled LGS. This study used an
active comparator arm in which add-on AEDs chosen by the
investigators at the time of randomization were added to the
baseline AEDs for subjects in the comparator any-other-AED
group, which may be more reflective of real-world AED
choices than the standard approach of choosing a compar-
ator AED a priori in clinical trials. This technique should
permit a clearer understanding of the safety and tolerability
of rufinamide compared with other commonly used
adjunctive AEDs in a pediatric population with inadequately
controlled LGS.
Interim safety results showed rufinamide to be safe and
well tolerated in these pediatric subjects1 to <4 years of age.
The incidence rates of SAEs and of TEAEs that resulted in
discontinuation from study drug or required study drug dose
adjustment, and TEAEs of special interest were low overall.
There were no laboratory-related SAEs and no AEs of over-
dose. The overall incidence of TEAEs was similar between the
rufinamide group and the any-other-AED group; incidence of
TEAEs resulting in discontinuation was also similar, occurring
in 2 subjects in the rufinamide group and 1 in the any-other-
AED group. The incidence of SAEs was similar in the rufina-
mide and any-other-AED groups, and all subjects recovered
from SAEs without sequelae. No subject died during the study
as of the data cutoff date. Additionally, there were no clini-
cally important mean changes in laboratory values, vital
signs, or ECGs. Based on this study, the safety profile of rufi-
namide is similar to that of any other AED as chosen by the
investigator. Thus far, as noted in the US Prescribing Infor-
mation for rufinamide, it appears that the safety profile ofFig. 2 e Box plots of weight-normalized apparent clearance (CL
concentrationetime curve.rufinamide in subjects 1 to <4 years of age is generally
similar to that in subjects aged 4 years with LGS.1
Results from the PK analysis demonstrate that the PK of
rufinamide in subjects aged 1 to <4 years is comparable to
that from previous analyses in subjects aged 4 years with
LGS. No adjustments are necessary to the body weight-based
dosing for rufinamide in subjects 1 to <4 years of age. The
PK of rufinamide was independent of dose and was not
significantly affected by age, gender, race, hepatic function, or
renal function. Coadministration of valproic acid significantly
reduced rufinamide clearance in subjects 1 to <4 years of
age, which was similar to results seen previously in subjects
aged 4 years1,17 (Fig. 3). This interaction has been investi-
gated in vitro, as well.18
Several other medications, including AEDs, are
commonly used in the treatment of LGS, and clobazam,
lamotrigine, topiramate and felbamate are FDA approved for
use in children aged 2 years.19e25 Based on PK and safety
studies, the Prescribing Information for lamotrigine, felba-
mate, and topiramate contains weight-based dosing recom-
mendations and adjustment guidance based on concomitant
AEDs. Clobazam is the only AED with no mention of dose
adjustment if the patient is on another AED. However, the
Prescribing Information does note that lower doses of drugs
metabolized by CYP2D6 may be required when used
concomitantly with clobazam, and a dose adjustment of
clobazam may be necessary when used with strong or
moderate CYP2C19 inhibitors.
The most important PK differences based on age are those
that result from changes in the efficiency of the processes
responsible for drug elimination. In general, age is considered
not to have a major influence on the absorption of drugs from
the gastrointestinal tract (except in the first few weeks of life).
Drug metabolizing capacity is reduced in newborns, but in-
creases rapidly during the first few weeks or months of life to
reach levels that are generally higher than those found in
adults. For lamotrigine, felbamate, and topiramate, CL/F
values have been found to be higher in children than in adults,
and, as a result, children would require larger dosages to
achieve serum drug levels comparable with those found in
adults.26 In contrast with this, no age-based difference was
seen with rufinamide.
Safety and effectiveness in patients <2 years of age have
not been demonstrated for other AEDs approved for LGS./F) and AUC by age category. AUC ¼ area under the
Fig. 3 e Box plots of weight-normalized apparent clearance (CL/F) and AUC by age category and concomitant valproic acid
use. AUC ¼ area under the concentrationetime curve.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 3 9 3e4 0 2400Study 303 will be the first to evaluate rufinamide in patients
as young as 1 year, and if current trends continue, it will
also be the first study to demonstrate that rufinamide
is safe in these very young patients. This interim analysis
did not capture efficacy results. A previous small,retrospective, open-label study in patients under 4 years of
age (mean age 39.5 months; range 22e48 months) indicated
that rufinamide was effective in LGS.27 Efficacy and final
safety results from the full 2-year duration of Study 303 are
forthcoming.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 3 9 3e4 0 2 4015. Conclusions
A 2-year multicenter, randomized, active-controlled, open-
label study to determine the effects of rufinamide in a pedi-
atric population 1 to <4 years of age with inadequately
controlled LGS is currently underway. Interim 6-month safety
results demonstrate that rufinamide is safe and well tolerated
in these very young subjects. Results of a PK analysis from this
study demonstrate that the PK profile of rufinamide in sub-
jects aged 1 to <4 years is comparable to that from previous
analyses in subjects aged 4 years with LGS. Overall, this
study should provide data that improve our understanding of
the LGS disease state in the 1 to <4 year age group and the
effects of rufinamide and other AEDs during a critical devel-
opmental period for pediatric patients with epilepsies of the
LGS clinical spectrum.Disclosures
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